EUVIMEDEUVIMED entdecken
Open Access

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib

Paulina Podszywałow-Bartnicka iD, Morgan Shine iD, Jing Lin iD, Karla M Neugebauer iD

Science Advances · 2026

DOI: 10.1126/sciadv.aea2475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Paulina Podszywałow-Bartnicka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Imatinib Mesylate, Alternative Splicing, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Transcription, Genetic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular stresses regulate transcriptional readthrough, whereby RNA polymerase II elongates past a gene’s polyadenylation cleavage site without RNA cleavage. Readthrough has been reported in several cancer types. Here, we use long-read sequencing of nascent RNA to quantify transcriptional readthrough in chronic myeloid leukemia (CML) cells and characterize early responses to the targeted therapeutic, imatinib. We show that the amount, length, and gene specificity of readthrough increase within 1 hour, before gene expression and alternative splicing alterations emerge. Notably, imatinib-dependent messenger RNA (mRNA) isoform changes involved “readthrough chimeras,” in which exons from an upstream gene are alternatively spliced to exons in a downstream gene. Altered mRNA isoforms and chimera levels were detected in imatinib-resistant K562 cells as well as cells of patients with CML. Thus, imatinib can provoke a cascade of early changes to transcription and splicing fidelity that may lead to longer-term adjustments in gene expression, cancer cell differentiation, and the development of therapy resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateAlternative SplicingLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTranscription, GeneticAntineoplastic AgentsHumansK562 CellsRNA, MessengerDrug Resistance, NeoplasmExonsCell Line, Tumor

Substanzen

Imatinib MesylateRNA, MessengerAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT, USA.

ORCID-Profile: Paulina Podszywałow-Bartnicka, Morgan Shine, Jing Lin, Karla M Neugebauer

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • NIEHS NIH HHS
  • National Institute of General Medical Sciences
  • Fulbright Program
  • TRANSLACORE Cost Action

Zitieren

APA

Podszywałow-Bartnicka, P., Shine, M., Lin, J., & Neugebauer, K. M. (2026). Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib. Science Advances. https://doi.org/10.1126/sciadv.aea2475

Vancouver

Podszywałow-Bartnicka P, Shine M, Lin J, Neugebauer KM. Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib. Science Advances. 2026. doi:10.1126/sciadv.aea2475

BibTeX
@article{PodszywaowBartnicka2026,
  author = {Podszywałow-Bartnicka, Paulina and Shine, Morgan and Lin, Jing and Neugebauer, Karla M},
  title = {Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aea2475}
}
Kostenlos starten →